Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPAC IV Oral Antibiotic Outpatient Therapy vs Placebo in Uncomplicated Acute Appendicitis
2023-506213-21-00Phase 4Authorised
- Sponsor
- Turku University Hospital
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in appendicitis comparing Oral moxifloxacin with Placebo (2 arms). Primary endpoint: 30-day treatment success. Planned start Oct 2023; status: authorised.
02
Drugs
moxifloxacin
03
Conditions
appendicitis
Beyond the preview
Go deeper on 2023-506213-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506213-21-00.